Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SOTROVIMAB Cause Chronic obstructive pulmonary disease? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Chronic obstructive pulmonary disease have been filed in association with SOTROVIMAB. This represents 0.2% of all adverse event reports for SOTROVIMAB.

7
Reports of Chronic obstructive pulmonary disease with SOTROVIMAB
0.2%
of all SOTROVIMAB reports
1
Deaths
5
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From SOTROVIMAB?

Of the 7 reports, 1 (14.3%) resulted in death, 5 (71.4%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SOTROVIMAB. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does SOTROVIMAB Cause?

Exposure during pregnancy (1,348) Infusion related reaction (275) Product storage error (259) Off label use (231) Pyrexia (185) Covid-19 (158) Nausea (135) Dyspnoea (134) Live birth (133) Pruritus (107)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which SOTROVIMAB Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

SOTROVIMAB vs SOVALDI SOTROVIMAB vs SOYBEAN OIL SOTROVIMAB vs SPARSENTAN SOTROVIMAB vs SPARTALIZUMAB SOTROVIMAB vs SPESOLIMAB-SBZO

Related Pages

SOTROVIMAB Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease SOTROVIMAB Demographics